BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced that its management will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Monday, April 13, 2026, at 8:45 am ET. Interested parties can access live and archived webcasts on the investors section of BioStem's website at ir.biostemtechnologies.com.
This presentation comes at a pivotal time for BioStem, as the company continues to expand its portfolio of advanced allograft solutions derived from perinatal tissue. BioStem leverages proprietary processing technologies—BioRetain®, CryoTek®, and SteriTek®—to preserve the natural properties of these tissues, supporting their use in clinical settings across a wide range of specialties. The company's quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices and current Good Manufacturing Processes.
The Needham conference provides a platform for BioStem to communicate its strategic vision and recent progress to investors and industry analysts. With a national commercial footprint and growing clinical research initiatives, BioStem is positioned to drive innovation in regenerative medicine. The company's portfolio includes brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™.
For more information about BioStem Technologies, visit their website at biostemtechnologies.com and follow them on X and LinkedIn. To stay updated, sign up for the company's email distribution list and follow the latest news in their newsroom at https://tinyurl.com/bsemnewsroom.
The announcement underscores BioStem's ongoing commitment to advancing regenerative medicine and its efforts to engage with the investment community. The presentation at the Needham conference is expected to provide deeper insights into the company's product pipeline, clinical developments, and market expansion strategies.
